Scientists from DuPont were honored for developing the insecticide DuPont Rynaxypyr (chlorantraniliprole). They are John H. Freudenberger, Ph.D.; Thomas P. Selby, Ph.D.; Daniel Cordova; George P. Lahm, Ph.D.; and Thomas M. Stevenson, Ph.D. Rynaxypyr has one of the lowest toxicity profiles of all insect-control products, including products derived from natural sources, yet is one of the most potent and selective insect-control products ever discovered.
Scientists from Merck & Co., Inc., became new Heroes for developing Isentress (raltegravir), a potent integrase inhibitor for the treatment of HIV-1 infection in patients as part of combination HIV therapy. They are David Askin, Ph.D.; Peter Maligres, Ph.D.; Joseph Vacca, Ph.D.; Guy Humphrey, Ph.D.; Michael Rowley, Ph.D.; John Wai, Ph.D.; Ralph Laufer, Ph.D.; Enzo Summa, Ph.D.; and Steven Young, Ph.D.
Scientists from Pfizer won the honor for developing Xalkori (crizotinib), a drug that fights a genetic defect causing some lung cancers. They are Jingrong Cui, Ph.D.; Michelle Tran-Dub; Pei-Pei Kung, Ph.D.; Mason Pairish; and Hong Shen.
Scientists from Vertex, a global biotechnology company, won the honor for developing KALYDECO (ivacaftor), a medicine for people with cystic fibrosis (CF) who have a specific mutation in their CF gene called the G551D mutation. They are Vijayalaksmi Arumugam, Ph.D.; Brian Bear, Ph.D.; Peter D. J. Grootenhuis, Ph.D.; Jason McCartney; Jinglan Zhou, Ph.D.; Anna Hazlewood; Sabine Hadida, Ph.D.; Adam Looker, Ph.D.; Bobbianna Neubert-Langille, Ph.D.; David Willcox, Ph.D.; Michael Ryan; and Zhifeng Ye, Ph.D.
|Contact: Michael Bernstein
317-262-5907 (Indianapolis Press Center, Sept. 6-11)